FDA: antibacterial Doribax associated with increased risk of death for ventilator patients with pneumonia


The FDA ( Food and Drug Administration ) has concluded that Doribax ( Doripenem ), an antibacterial drug that has been used to treat patients who develop pneumonia while on ventilators, carries an increased risk of death and lower clinical cure rates compared to use of Imipenem and Cilastatin for injection ( marketed in the U.S. under the name Primaxin ).
Based on the analysis of data from a three-year clinical trial that was prematurely stopped in 2011 due to these safety concerns, FDA has approved changes to the Doribax drug label that describe these risks.

Doribax is not approved to treat any type of pneumonia, and the revised label also includes a new warning about this unapproved use.
Health care professionals should consider whether the benefits of Doribax treatment are likely to exceed its potential risks in patients who develop pneumonia while on ventilators.

Doribax is still considered safe and effective for its FDA-approved indications: treatment of adults with complicated intra-abdominal infections and complicated urinary tract infections, including kidney infections called pyelonephritis.

In the clinical trial that was stopped early, patients with ventilator-associated bacterial pneumonia received either 7-day Doribax treatment or 10-day treatment with Imipenem and Cilastatin, another antibacterial drug.
In the intent-to-treat population, the 28-day all-cause mortality was higher in the Doribax arm ( 23.0%; n=31/135 ) than in the Imipenem and Cilastatin arm ( 16.7%; n=22/132 ) . Clinical cure rates were also lower in the Doribax arm. ( Xagena )

Source : FDA, 2014

XagenaMedicine_2014



Indietro

Altri articoli

Fungal infections that are resistant to treatment are an emerging public health problem, but everyone has a role in preventing...


The U.S. Food and Drug Administration ( FDA ) has advised that the serious side effects associated with fluoroquinolone antibacterial...


Office of Orphan Products Development ( OOPD ) of the Food and Drug Administration ( FDA ) has granted orphan...


The FDA ( Food and Drug Administration ) has approved Xtoro ( Finafloxacin otic suspension ), a new drug used...


The FDA ( Food and Drug Administration ) has approved Sivextro ( Tedizolid phosphate ), a new antibacterial drug, to...


Use of Nitrofurantoin for urinary tract infections is contraindicated in patients with less than 60 mL/min creatinine clearance. Healthcare professionals...


Chronic bacterial prostatitis ( CBP ) is frequently diagnosed in men of fertile age, and is characterized by a disabling...


The Food and Drug Administration ( FDA ) warned the public that Azithromycin ( Zithromax or Zmax ) can cause...


The FDA ( Food and Drug Administration ) has approved Altabax ( Retapamulin ointment ) for topical treatment of impetigo...